2SEVENTY BIO INC's ticker is and the CUSIP is 901384107. A total of 146 filers reported holding 2SEVENTY BIO INC in Q2 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $6,507,200 | -49.6% | 1,660,000 | +30.0% | 0.02% | -50.0% |
Q2 2023 | $12,922,754 | +499.7% | 1,276,952 | +504.4% | 0.04% | +442.9% |
Q1 2023 | $2,155,046 | -18.3% | 211,279 | -25.0% | 0.01% | -22.2% |
Q4 2022 | $2,639,061 | +14.5% | 281,650 | +77.8% | 0.01% | 0.0% |
Q3 2022 | $2,305,000 | -26.7% | 158,450 | -33.5% | 0.01% | -30.8% |
Q2 2022 | $3,146,000 | -40.7% | 238,300 | -23.3% | 0.01% | -38.1% |
Q1 2022 | $5,301,000 | -64.7% | 310,700 | -47.0% | 0.02% | -65.0% |
Q4 2021 | $15,037,000 | – | 586,707 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 4,890,706 | $49,493,945 | 6.81% |
CHI Advisors LLC | 852,007 | $8,622,311 | 2.62% |
Casdin Capital, LLC | 2,023,913 | $20,482,000 | 1.79% |
Newtyn Management, LLC | 737,744 | $7,465,969 | 1.76% |
Bain Capital Life Sciences Investors, LLC | 1,408,901 | $14,258,078 | 1.47% |
DAFNA Capital Management LLC | 496,416 | $5,023,730 | 1.37% |
AlphaCentric Advisors LLC | 180,000 | $1,821,600 | 1.01% |
SECTORAL ASSET MANAGEMENT INC | 462,485 | $4,680,348 | 0.78% |
CLOUGH CAPITAL PARTNERS L P | 529,110 | $5,354,593 | 0.54% |
Bleichroeder LP | 255,230 | $2,582,928 | 0.52% |